194 related articles for article (PubMed ID: 20567002)
1. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.
Ladenstein R; Valteau-Couanet D; Brock P; Yaniv I; Castel V; Laureys G; Malis J; Papadakis V; Lacerda A; Ruud E; Kogner P; Garami M; Balwierz W; Schroeder H; Beck-Popovic M; Schreier G; Machin D; Pötschger U; Pearson A
J Clin Oncol; 2010 Jul; 28(21):3516-24. PubMed ID: 20567002
[TBL] [Abstract][Full Text] [Related]
2. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
4. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
5. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
Kushner BH; Heller G; Kramer K; Cheung NK
Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
[TBL] [Abstract][Full Text] [Related]
7. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma.
Michon JM; Hartmann O; Bouffet E; Meresse V; Coze C; Rubie H; Bordigoni P; Cattiaux E; Ward N; Bernard JL; Lemerle J; Zucker JM; Philip T
Eur J Cancer; 1998 Jun; 34(7):1063-9. PubMed ID: 9849455
[TBL] [Abstract][Full Text] [Related]
8. Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Garaventa A; Poetschger U; Valteau-Couanet D; Luksch R; Castel V; Elliott M; Ash S; Chan GCF; Laureys G; Beck-Popovic M; Vettenranta K; Balwierz W; Schroeder H; Owens C; Cesen M; Papadakis V; Trahair T; Schleiermacher G; Ambros P; Sorrentino S; Pearson ADJ; Ladenstein RL
J Clin Oncol; 2021 Aug; 39(23):2552-2563. PubMed ID: 34152804
[TBL] [Abstract][Full Text] [Related]
9. Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.
Peinemann F; van Dalen EC; Berthold F
Klin Padiatr; 2016 Apr; 228(3):130-4. PubMed ID: 27043079
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
[TBL] [Abstract][Full Text] [Related]
11. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study.
Amoroso L; Erminio G; Makin G; Pearson ADJ; Brock P; Valteau-Couanet D; Castel V; Pasquet M; Laureys G; Thomas C; Luksch R; Ladenstein R; Haupt R; Garaventa A;
Cancer Res Treat; 2018 Jan; 50(1):148-155. PubMed ID: 28324923
[TBL] [Abstract][Full Text] [Related]
12. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
[TBL] [Abstract][Full Text] [Related]
13. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
Whittle SB; Smith V; Silverstein A; Parmeter M; Minard CG; Bernhardt MB; Zage PE; Venkatramani R; Nuchtern JG; Heczey A; Russell HV; Shohet JM; Foster JH
Pediatr Blood Cancer; 2020 Oct; 67(10):e28417. PubMed ID: 32729196
[TBL] [Abstract][Full Text] [Related]
14. Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma.
Carroll C; Clinton F; Smith A; Fox A; Capra M; Pears J; Owens C
Pediatr Blood Cancer; 2018 Dec; 65(12):e27386. PubMed ID: 30230225
[TBL] [Abstract][Full Text] [Related]
15. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
16. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
[TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
